INT200803

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2006
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 1.23
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Stat5a) nucleus (Stat5a) DNA binding (Stat5a)
cytoplasm (Stat5a) signal transducer activity (Stat5a)
Anatomy Link Frequency
spleens 1
Stat5a (Mus musculus)
Pain Link Frequency Relevance Heat
fibrosis 3 30.00 Quite Low
cva 1 12.40 Low Low
Potency 6 5.00 Very Low Very Low Very Low
cytokine 5 5.00 Very Low Very Low Very Low
headache 4 5.00 Very Low Very Low Very Low
Parenteral administration 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
backache 2 5.00 Very Low Very Low Very Low
pruritus 2 5.00 Very Low Very Low Very Low
anesthesia 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myeloid Leukemia 87 99.84 Very High Very High Very High
Leukemia 31 93.04 High High
Philadelphia Chromosome 25 92.84 High High
Hematological Disease 6 81.64 Quite High
Arrhythmias 2 Under Development 2 69.96 Quite High
Pressure And Volume Under Development 4 69.00 Quite High
Erythrocytosis 35 61.04 Quite High
Myelofibrosis 18 59.76 Quite High
Hemolysis 2 53.88 Quite High
Chronic Myeloid Leukemia 6 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
There was constitutive activation of Stat5 and detectable expression of the Stat5 target Bcl-XL in BM of both normal and polycythemic mice, with increased Stat5 phosphorylation and Bcl-XL in spleens from JAKV617F recipients, although this could in part reflect the increase in splenic myeloerythroid cells in these mice.
Phosphorylation (phosphorylation) of Stat5 in spleens
1) Confidence 0.59 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762384 Disease Relevance 0.24 Pain Relevance 0
Recently, it was demonstrated that nilotinib inhibited mitogen-activated protein kinase (MPAK), AKT and STAT5 phosphorylation in CML CD34+ cells in the absence of growth factors, but did not suppress AKT and STAT5 activity and resulted in increased MAPK activity in the presence of growth factors.
Phosphorylation (phosphorylation) of STAT5 associated with myeloid leukemia
2) Confidence 0.42 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994207 Disease Relevance 0.44 Pain Relevance 0
In patients with AP or BP who received nilotinib 400 mg or 600 mg twice daily, a significant decrease in phosphorylation of AKT, CRKL, STAT1, and STAT5 was observed on day 15 of therapy compared with baseline (Kantarjian et al 2006).
Phosphorylation (phosphorylation) of STAT5
3) Confidence 0.42 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994207 Disease Relevance 0.55 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox